Development of novel cell and gene therapies

$0ZIAFY2022CLNIH

Clinical Center

Investigators

Linked publications, trials & patents

Paper 38374090 Paper 37939262 Paper 37394115 Paper 36099324 Paper 34302788 Paper 33993466 Paper 33956057 Paper 33823169 Paper 33764809 Paper 33632869 Paper 33558725 Paper 33472742 Paper 33232788 Paper 32612991 Paper 32286905 Paper 31278568 Paper 31178392 Paper 30871636 Paper 30012146 Paper 29812997 Paper 29540180 Paper 29368612 Paper 29155426 Paper 28447618 Paper 28295178 Paper 28236305 Paper 27412889 Paper 27226436 Paper 27210719 Paper 26823601 Paper 26505619 Paper 26190358 Paper 26116089 Paper 26071480 Paper 25937830 Paper 25882666 Paper 25532725 Paper 25452614 Paper 25319501 Paper 25223845 Paper 25188417 Paper 25064527 Paper 24844857 Paper 24573369 Paper 24452962 Paper 24422625 Paper 24368014 Paper 24117879 Paper 23992830 Paper 23813900 Paper 23426943 Paper 23148746 Paper 23109243 Paper 22586033 Paper 22547579 Paper 22421946 Paper 22420641 Paper 22309358 Paper 22272697 Paper 22185188 Paper 21740581 Paper 21684345 Paper 21684344 Paper 21501511 Paper 21304401 Paper 21258790 Paper 20635956 Paper 20628641 Paper 20350323 Paper 20078383 Paper 19776705 Paper 19431094 Paper 19342965 Paper 18676758

Abstract

The Center for Cellular Engineering (CCE) is working to develop and improve cancer cellular therapies including Dendritic Cell (DC) therapies, chimeric antigen receptor (CAR) T cell therapies and T cell engineered to express T cell receptors (TCRs) specific to tumor antigens. The laboratory is working to improve the methods used to produce Bone Marrow Stromal Cells (BMSCs) and induced pluripotent stem (iPS) cells for regenerative medicine applications. The CCE New Production Management (NPM) laboratory has developed and is manufacturing several CAR T cell therapies. CD22-CAR T cells and CD19/CD22-bispecific T cells are being manufactured in order to treat pediatric patients with B cell leukemia. Manufacturing of CD30-CAR T cells has recently been initiated. These CAR T cells are being used to treat adults with lymphomas. The laboratory has also developed anti-B Cell Maturation Antigen (BCMA) CAR T cells and anti-SLAMF7-CAR T cells to treat patients with multiple myeloma. The laboratory has developed procedures to manufacture CD19/CD22- CAR T cells using a completely automated instrument. This automated instrument has been used to develop anti-Glypican-3 CAR T cells which will be used to treat patients with hepatocellular carcinoma. Human Papillomavirus (HPV) infection is associated with a number of cancers. The NPM laboratory has developed a method to produce T cells that express a T cell receptor (TCR) that is specific for the HPV-16 oncoprotein E7. These cells will be used to treat patients with HPV-associated cervical and oropharyngeal cancers. The laboratory has also recently completed the development of KK-LC-1 specific TCR engineered T-cells. These cells will also be used to treat patients with HPV-associated cancers. The Cell Processing Laboratory is collaborating with investigators in the National Eye Institute to develop methods to manufacture iPS cells from CD34+ cells isolated from the blood and to differentiate the iPS cells in retinal pigment epithelial (RPE) cells. The RPE cells will be used to treat patients with age related macular degeneration.

View original record on NIH RePORTER →